MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Charts
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
NMR stock logo

NMR

Nomura Holdings, Inc.

$10.13
0.08
 (0.75%)
Exchange:  NYSE
Market Cap:  29.591B
Shares Outstanding:  1.963B
Delayed data
Calculate NMR Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Financial Services
Industry:  Financial – Capital Markets
   
CEO:  Kentaro Okuda
Full Time Employees:  28677
Address: 
13-1, Nihonbashi 1-chome
Tokyo
TY
103-8645
Website:  https://www.nomura.com

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

It’s free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

No earnings call materials on file for this symbol yet.

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

🔒 You are currently logged out

Login

It's free

(* All numbers are in thousands)

Balance Sheet

🔒 You are currently logged out

Login

It's free

(* All numbers are in thousands)

Cash Flow Statement

Year202420252026
Operating Cash Flow132,640,000-678,611,000-842,960,000
Capital Expenditure-145,784,000-189,971,000-353,818,000
Free Cash Flow-13,144,000-868,582,000-1,196,778,000
Net Income177,220,000347,255,000374,382,000
Net Change in Cash478,170,000126,419,000-106,719,000

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)2,070,364,865.971Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)2,328,854,404.128Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)2,207,198,327.276Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)261,152,737.237Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)293,758,222.167Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)278,412,706.024Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)401,941,302.395Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)468,499,185.238Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)437,174,246.395Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)525,651,141.216Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)591,279,824.816Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)560,392,198.831Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)143.650Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)153.940Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)132.070Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)2Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)1Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
28.747B  ?P/S
 (TTM)
: 
0.03
?Net Income
 (TTM)
: 
1.147B  ?P/E
 (TTM)
: 
0.31
?Enterprise Value
 (TTM)
: 
38.685T  ?EV/FCF
 (TTM)
: 
0
?Dividend Yield
 (TTM)
: 
3.32%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
395.36%  ?ROIC
 (TTM)
: 
22.13%
?Net Debt
 (TTM)
: 
171.943B  ?Debt/Equity
 (TTM)
: 
10.19
?P/B
 (TTM)
: 
1.17  ?Current Ratio
 (TTM)
: 
0.85

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
2,017.78Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

Strengths (preview)

  • Robust Revenue Growth: Nomura Holdings reported a 16% increase in group net revenue to JPY 523.3 billion in Q1 2023, as highlighted in the earnings call transcript, reflecting strong performance across key business segments and effective operational execution.
  • Positive Financial Metrics: Key metrics such as return on equity (ROE) and return on invested capital (ROIC) from the TTM data indicate efficient use of capital, positioning NMR favorably within the financial services sector.
  • Strong Operating Cash Flow: Cash flow statements reveal consistent net cash provided by operating activities, supported by healthy net income and depreciation adjustments, ensuring liquidity for reinvestment and debt management.

Log in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.

Log in to continue

Log in with Full Access for the complete SWOT analysis.

Login — it's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about NMR valuation

Is Nomura Holdings, Inc. (NMR) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Nomura Holdings, Inc. (NMR) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is NMR a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether NMR trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is NMR’s P/E ratio?

You can see NMR’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for NMR?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is NMR a good long-term investment?

Whether NMR fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

NMR

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

0.75
MARKETSnap

Trading Metrics:

Open: 10.09   Previous Close: 10.05
Day Low: 10.09   Day High: 10.16
Year Low: 6.71   Year High: 10.16
Price Avg 50: 9.51   Price Avg 200: 8.58
Volume: 303051   Average Volume: 1.27M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free

NMR full analysis

10/09/2025

Welcome to MARKETSNAP’s SWOT analysis for Nomura Holdings, also known by its ticker NMR. If you’re a long-term investor looking to dig into a major player in the financial world, you’ve come to the right place. Today, we’re breaking down Nomura Holdings, a heavyweight in the investment banking and financial services space, to see what makes it tick, where it’s vulnerable, and what could shape its future. Let’s dive in with a quick overview before we get into the nitty-gritty.…

Open MarketSnap Listen

Log in to continue

Log in to see the full analysis preview and audio links.

Login — it's free

See in Nexus

Relevant news

Recent Price Trend in Nomura (NMR) is Your Friend, Here's Why
17-08-2026 09:56
Recent Price Trend in Nomura (NMR) is Your Friend, Here's Why
Nomura (NMR) Is a Great Choice for 'Trend' Investors, Here's Why
31-07-2026 09:55
Nomura (NMR) Is a Great Choice for 'Trend' Investors, Here's Why
Nomura Holdings, Inc. (NMR) Q1 2027 Earnings Call Transcript
29-07-2026 09:43
Nomura Holdings, Inc. (NMR) Q1 2027 Earnings Call Transcript
Nomura: Favorable Prospects For Core Segments
09-07-2026 09:13
Nomura: Favorable Prospects For Core Segments
Nomura Climate Solutions Fund Q1 2026 Strategic Positioning
04-06-2026 23:35
Nomura Climate Solutions Fund Q1 2026 Strategic Positioning
Valion Bio's Velocity Bioworks Secures Exclusive Commercial License to LarmorBio's BioScan-NMR™ Platform
14-05-2026 16:31
Valion Bio's Velocity Bioworks Secures Exclusive Commercial License to LarmorBio's BioScan-NMR™ Platform

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Philosophy
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlist & Portfolio Watchlist & Portfolio
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read